Judy. time today. you, everyone for you and your thank afternoon, Thank Good
IV therapeutic numerous business initial continuing release in first: update our fronts, and progress international status an we in our of update update our the high focus data of activities for and our end-stage medical Triferic; second, on on our today third, the disease. As Triferic our potential on this world platform providing Triferic; date; we our our an finally, renal shared outside PDUFA real program; launch afternoon, updates indications on XX March additional including key a are recent progress next, of of in with press Dialysate
transform get not Medical, also in hemodialysis me anemia into to Rockwell I is a way the across therapeutic Before metrics, let undergoing the only variety overarching goal ESRD briefly patients our managed of indications. treatment, is which reiterate but wide at
take on care. to are the X not focused We in overnight, changing as we stated but years will of happen previously, achieve standard have And ESRD. this to will X
in therapeutic real as disease addresses common this initial side focus end-stage population. in anemia effect Our the the patient
and levels of important the and other the that risks events. overload with to grow. problem XXX exciting and therapeutic an believe million hemodialysis hemodialysis are we iron and the traditional treatments receive without adverse numbers delivers many you million hemoglobin annually new the hypertension, maintains more remind patients the market X of increasing And and ferritin with that diabetes, is irons. than likely Triferic translates of chronic of of size and than hemodialysis iron these the which experienced To inflammation opportunity, Now, without avoids IV need year. into obesity increasing toxicity worldwide, that people more rates And patients Triferic each
includes Triferic has to way disrupt anemia. to and Triferic providers platform, U.S the which IV potential Triferic healthcare treat and Dialysate in globally both the Our approval, pending the FDA
the first in Let we last of which overview Dialysate States approved me launched May with formulation, FDA start our off United an in year. of Triferic,
to part and clinical for clinics program as earlier of launch when Our fourth they an their patients. represents year year, us to-date. Dialysate of quarter been conversion important rate dialysis now sample have saw validation the evaluation very believe last three has very introduced in this allows for And see clinics this clinics benefits customers. successful Triferic initiate that completed to we for converted it XX% valuation during which with the Triferic that contracted the therapy program a program, and months we consistent is in the the we
a the dialog of value the helps which and stated reinforce Triferic regarding have long-term. we Triferic evaluation that Triferic as program believe clinics to implementation benefits interactions past, we smooth for of the And the the of with allow in we during
We the launch as with include to from our a outset the a first or small we Dialysate were ultimately also the Triferic, November efforts broaden pleased are signed said organization, plan to independent organizations MDO. with customer large acquisition dialysis initial and and medium our dialysis we of dialysis contract last our medium-size targets And of organizations. size
patients. for this So, key it their targeting this estimated is with gives began significant signing clinics system, XXX access clinics Triferic, an and approximately of launch Triferic. introduce that working MDO within within MDO representing are Dialysate KOLs system this fully XX,XXX to our within the X by We us leading X appropriate to
to Triferic. the part expecting database pharmacoeconomic to to as us closely acceleration of in in and initiated XXXX, see to end clinics training, building and implementation to option Dialysate launch X Triferic. the with are first Triferic the of the this measures clinical to expand And we place, Dialysate support system of of appropriate contract, to fully the we continued are data, converted first use year And importantly year have growing and that months of half of the have clinics within these their MDO working with the which two adoption of been add are benefits ensure of we provide as XXXX, purchasing a As result. during will and
XX, a in XXXX Let and patients. me provide at terms of of stood snapshot December where clinics we
representing into XXX we at than or contract of more to XXX entered quarter, more the in XX% contracts clinics XX a that XX, patients September XXXX. place additional compared the XX number increase to During contracts, December XX of And than representing under patients. fourth brings in
basis. over In patients addition, XX% had of of XXX annualized September of representing treatments treatments more XX, than an under to an in That we clinics, were Furthermore, on QX, XX% increase various Triferic stages as annualized evaluation of From XX, to of program. XXXX. contract to we XX saw December additional XXX,XXX contract. QX an in number on the customers more XXXX, equates increase under compared than ongoing
inroads We large gaining we accelerate that anemia believe the it in we the around and XXXX. market growing in States. to the If make significant go as Medical through into are continues traction Rockwell uptake trends and these will, ESRD United as stands believe market management will
our to now IV of formulation turn me Let Triferic.
XX PDUFA looking platform. approval innovative to March days forward receiving Triferic our our now of we We this extension of from just are are XX launching and date and
reminder, pursuant to is developed and IV designed that Special a an Triferic our adult hemodialysis a for for was SPA Assessment, review. As patients intravenous through equivalence to be or Dialysate administration FDA acceptable Protocol to agreed Triferic would approach the which
to of regardless based Triferic number of individuals IV dry and great the to approved, where centers the cases dialysis and recent of if being is IV been provides using bedside. allows clinics hemodialysis used. more bicarbonate. shifting in bicarbonate bicarbonate deal treatment have mode they a administer It to delivery bicarbonate can from clinic for flexibility Triferic The customize that a in liquid U.S. also Now at In on patients reliance years, the dry centers appropriate central loop. formulation hemodyalysis a is of away our dialysis
previously, the dry that have we require or as markets many in centers bicarbonate noted cartridges dialysis And international used the already IV bags formulation.
the both [indiscernible] bicarbonate two including certain should So internationally. these Triferic clinics marketplace. the responders hyper in Together, of expanding ferritin are formulations such our And approach, considerations or the the domestically offering treat flexibility, we the Triferic under preferred approval developed Dialysate and to potential strategy delivery as ESA impression vis-à-vis flexibility as high a FDA offer IV believe our Triferic we adoption patients for for of will with finalized support dialysis treatment subpopulation and patients positioning currently some level. and
QX, plans of of our leverage apply rolling launch Dialysate Dialysate launch approved, commercialization and the we In evaluation have if our plan many infrastructure engaging launch for invest helping the groundwork learnings from of the in time programs to for clinics months. we Triferic understand IV unique we IV Triferic. mechanism learnings and X them out will Triferic, QX, to lay benefits the established from Initially with Triferic. for we last of terms In IV the for plan will action as version the the we and
in of commence year Triferic We will of targeted X reach as commercial then completion IV month in the for IV evaluation plan quarter clinics to this Triferic adoption fourth program. their the early point sales
while enables We we our forward broadly will the cost need to to Triferic significant structure the the attractive update ensuring for on is reimbursed anticipate ESRD in to an portfolio gross Triferic the the to we therapy last few Triferic that on call, IV accessible stated weeks. we patients us margin, an importantly, THE extension providing be As it bundle, make who that but believe this transformational within look most. next
XXXX, strengthen capabilities. to During quarter also we and continue the of fourth medical our enhance
Fishbane, Steve expanded on and MD; Jay our the Hoffman addition advising Dr. Medical had a as are board anemia three had with these strategy advisory renowned Chief Specifically, for new with experience Marc and who we hired MD impact Officer physicians our nephrologists positive MD; Triferic. of Besarab, Wish, peak and our Anatole already world medical renal
We medical companies kidney factor global public experiences to that clinical emerging HIF, Directors. than more developing development also in based added or policy countries. of including anemia, Russell includes Ellison, address pharmaceutical the four the large of our held affairs deep roles Executive His markets experience health Dr. prolyl developing or Ellison Chief leadership regulatory for of affairs hydroxylase is a PHIs. with Executive and biotechnology Directors, has products positions renal Medical inhibitors decades. broad Dr. hypoxia-inducible in and expertise space understanding and renal therapeutic in Ellison in Board strategy disease major on companies both MD and Board medical
We add key centers to influential of of centers also a number base excellence our to XXXX. expect engage customer in these with continued have to and
We clinics review the now have for with of first more the clinics world program. key and from program in year with real our to the the patients analysis during format number external data double first vendors X program XXX quarter in real our in data of trends. we and expanded And world than expect been the working with we we the X XXXX, ending over Finally, have clinics program. to data data the
and industry they to at utilization traditional the database physicians proactively deductions stable data expand pursue published prestigious are And and real we our the at indicates we or presented with these refine to in hemoglobin maintenance continue as centers of dialogue irons and Our seeing have analysis that very world conferences. will our ESAs. opportunities IV evidence, of
said now billion. Let for see of the States. opportunity we Triferic And all of alone market in have large in outside a Triferic for opportunity. opportunities me to The Triferic global $X turn is United we along, potentially as hemodialysis excess as
of these into Limited partnerships into Triferic subsidiary wholly with rights markets. for a announced Sun important position Pharmaceutical Pharma establish our that Industries India. expand license to or to supply working are owned We ourselves and the In footprint and Sun commercialize January, entered in agreements to we
about Sun throughout franchise company this promote and $X nephrologists that and in are excited than leading nephrology is use Pharma annual We to India. opportunity. partnerships billion It with India it globally. very sales will experience market Triferic distribution pharmaceutical the more license with largest has to in a
We fee our an exclusive we Sun responsible clinical, payments milestone regulatory and will net upfront activities. Sun Pharma India Together, commercialization execution the will all receives development will for and for be commercialization will Medical and eligible in royalties map for details sales. supply be and Triferic out be and Triferic and developments Pharma will on and partner. Rockwell
Triferic China. with potential are submission. trial Wanbang for PK a to with approval met completed in meeting that the December our And be also through the the a In China. needed additional while Biopharmaceutical studies support would PK was NMPA, an had XXXX commercialize to in in FDA discuss and Wanbang we indicated a and to regulatory that we studies know, China’s As clinical acknowledged you to the it submission NMPA the objective, equivalent partner, we XXXX, working
study the the its for CRO So since to with initiating have drastic Japan. the selected continuing Canada, other XXXX. the progress in including in the the Wanbang And clinical well and of required regulatory year. moving to submission potential in later for with as December are or geographies, discussions our awaiting meeting, we clinical NDS IV four Wanbang move we licensing is Triferic key to been continued in are have FDA Options body our forward. options forward and has development clinical engage study with submission a goal and approval submission ready decision to our And partners before and with Europe the finally, make this we partner,
initiatives a underway share to now other some take Let moment me at Rockwell.
Triferic for mentioned wide a identify the in and a other future a launched anemia earlier, I managed variety disease prioritize initiative As that of to therapeutic has end, have therapeutic transform development. way to the unique indications strategic And that is potential states. we to is
indications platform a and this We have plans and focus very an established year. This to a resources internal team comprised project on have update of hope we later external to plays to as this for our total on iron such technology exciting cardiovascular a we critical build oncology. us the as project look disease, in role out parenteral and other or address where nutrition is
We creating the and the XXXX for for was new value Medical. we years summary, Triferic for submitted lay We expanded and Dialysate In a future application to commercial and year success, to Triferic, groundwork company medical developed in our to additional U.S. Rockwell infrastructure position IV pivotal milestones the the in come. launched began drug for
IV seek steps U.S. outside as U.S., the XXXX more for build continue Triferic and believe we Triferic approval for our progress to for Rockwell of Triferic, ahead, success for Dialysate end-stage we year for an take our Looking outside will disease. in concrete Triferic position exciting use of upon early renal signs be the also
CFO, the to I over will review Angus? turn now quarter Smith Angus call our fourth financials. to our
